134 related articles for article (PubMed ID: 25171649)
1. Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failure.
Moe MM; Fernandez Teruel C; Soto-Matos A
Chemotherapy; 2013; 59(6):458-60. PubMed ID: 25171649
[TBL] [Abstract][Full Text] [Related]
2. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
3. Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.
Baldi GG; Di Donato S; Fargnoli R; Dona M; Bertulli R; Parisi E; Fantini L; Sbaraglia M; Panella M
Anticancer Drugs; 2016 Oct; 27(9):908-13. PubMed ID: 27348763
[TBL] [Abstract][Full Text] [Related]
4. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
Pick AM; Nystrom KK
J Oncol Pharm Pract; 2010 Dec; 16(4):269-72. PubMed ID: 20015930
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
Thariat J; Etienne-Grimaldi MC; Launay-Vacher V; Soto-Matos A; Fernandez-Teruel C; Ghafari T; Marcy PY; Milano G; Renée N; Gastaud L; Thyss A
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1363-7. PubMed ID: 21850465
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
8. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
9. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
11. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis.
Schur S; Lamm W; Köstler WJ; Hoetzenecker K; Nemecek E; Schwameis K; Klepetko W; Windhager R; Brodowicz T
Anticancer Drugs; 2013 Aug; 24(7):725-30. PubMed ID: 23728219
[TBL] [Abstract][Full Text] [Related]
13. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
Blay JY; Italiano A; Ray-Coquard I; Le Cesne A; Duffaud F; Rios M; Collard O; Bertucci F; Bompas E; Isambert N; Chaigneau L; Cassier P; Bui B; Decanter G; Derbel O; Coindre JM; Zintl P; Badri N; Penel N
BMC Cancer; 2013 Feb; 13():64. PubMed ID: 23388156
[TBL] [Abstract][Full Text] [Related]
16. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
17. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Kasper B; Schmitt T; Wuchter P; Dimitrakopoulou-Strauss A; Ho AD; Egerer G
Mar Drugs; 2009 Jul; 7(3):331-40. PubMed ID: 19841717
[TBL] [Abstract][Full Text] [Related]
18. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
Blomqvist C; Johansson R; Tarkkanen M
Ann Oncol; 2011 Apr; 22(4):988. PubMed ID: 21345940
[No Abstract] [Full Text] [Related]
20. [Trabectedin registry].
Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
